

# Marcin Skrzypski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4498148/publications.pdf>

Version: 2024-02-01

22  
papers

1,086  
citations

567281

15  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

2103  
citing authors

#	ARTICLE	IF	CITATIONS
1	BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer. PLoS ONE, 2007, 2, e1129.	2.5	200
2	Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncology, The, 2007, 8, 889-897.	10.7	140
3	An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non-Small-Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 284-290.	7.0	134
4	Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clinical Cancer Research, 2008, 14, 4794-4799.	7.0	99
5	A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma. Clinical Cancer Research, 2008, 14, 5565-5570.	7.0	77
6	A clonal expression biomarker associates with lung cancer mortality. Nature Medicine, 2019, 25, 1540-1548.	30.7	75
7	MicroRNA in lung cancer diagnostics and treatment. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 717, 25-31.	1.0	52
8	Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer. Clinical and Experimental Metastasis, 2016, 33, 765-773.	3.3	52
9	MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma. Lung Cancer, 2018, 118, 111-118.	2.0	38
10	Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. Oncogene, 2019, 38, 180-193.	5.9	35
11	Main Histologic Types of Non-Small-Cell Lung Cancer Differ in Expression of Prognosis-related Genes. Clinical Lung Cancer, 2013, 14, 666-673.e2.	2.6	34
12	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. Cancer Treatment Reviews, 2018, 66, 114-121.	7.7	28
13	Analysis of Safety, Risk Factors and Pretreatment Methods during Rush Hymenoptera Venom Immunotherapy. International Archives of Allergy and Immunology, 2008, 147, 241-245.	2.1	27
14	Quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR) in translational oncology: Lung cancer perspective. Lung Cancer, 2008, 59, 147-154.	2.0	26
15	P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with non-small cell lung carcinoma. Cancer, 2004, 100, 1951-1960.	4.1	20
16	Keratin 7 expression in lymph node metastases but not in the primary tumour correlates with distant metastases and poor prognosis in colon carcinoma. Polish Journal of Pathology, 2016, 3, 228-234.	0.3	14
17	Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations. BMC Genomics, 2015, 16, 752.	2.8	12
18	The Role of TRAF4 and B3GAT1 Gene Expression in the Food Hypersensitivity and Insect Venom Allergy in Mastocytosis. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 497-503.	2.3	9

#	ARTICLE	IF	CITATIONS
19	Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors. <i>Wspolczesna Onkologia</i> , 2017, 3, 254-258.	1.4	8
20	Cancer cachexia in thoracic malignancy: a narrative review. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 316-322.	1.3	6
21	9th Central European Lung Cancer Conference in Gdańsk. <i>Lung Cancer</i> , 2005, 49, 281-284.	2.0	0
22	Can an Integrative SNP Approach Substitute Standard Identification in Comprehensive Case/Control Analyses?. <i>Advances in Intelligent Systems and Computing</i> , 2019, , 123-130.	0.6	0